J&J strikes up to $925M deal with Sail Biomedicines, secures option to buy for $2.58B

Johnson & Johnson announced a collaboration with Flagship Pioneering’s Sail Biomedicines to develop in vivo CAR‑T therapies for immune‑mediated diseases. The agreement provides up to $925 million in funding, including an initial $785 million payment that features a $465 million equity investment in Sail and up to $140 million in development milestones.

The partnership also gives J&J an exclusive right to acquire Sail Biomedicines later for $2.58 billion. While the company says the option could be exercised in the near term, no specific timeline or guarantee of a takeover was disclosed.

Analysts view the deal as a strategic move for J&J’s immunology research pipeline, though they note the potential acquisition could dilute earnings in the coming years.